Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.45 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311081 | 0.83 | PRKDC (0.43) | PRKDCNMT2NMT1GRM5TP53 | |
| SCHEMBL1232966 | 0.80 | MCHR1 (0.49) | NMT1CYP3A4KITGRM4MAOB | |
| SCHEMBL203370 | 0.80 | MAOB (0.41) | PRKDCNMT2NMT1NPC1RAB9A | |
| SCHEMBL1233388 | 0.76 | PRMT5 (0.39) | NMT1CYP3A4KITGRM4PRMT5 | |
| SCHEMBL1232944 | 0.74 | CYP8B1 (0.47) | NMT1KITPRMT5 | |
| SCHEMBL1233682 | 0.73 | CYP8B1 (0.44) | NMT1KITPRMT5 | |
| SCHEMBL4239447 | 0.73 | NPC1 (0.49) | MAPTNPC1RAB9ACYP3A4KIT | |
| SCHEMBL2059219 | 0.71 | BRD4 (0.44) | PRKDCNMT2NMT1CYP3A4KIT | |
| SCHEMBL1486838 | 0.71 | BRD4 (0.46) | NMT2NMT1CYP3A4KITPARP14 | |
| SCHEMBL21865485 | 0.70 | CYP3A4 (0.51) | PRKDCNMT2NMT1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093390-B2 | Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1845986-A2 | SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C]RING COMPOUNDS AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086633-A2 | SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | IL2, IFNG, IL4 | PRKDC 3764/4885NMT2 3470/4885NMT1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.